对MKI67在癌症中的预后价值,表达特征和免疫相关性的全面分析
Xiaolan Pan1, Caibiao Wei1, Jingyu Su2
1Department of Clinical Laboratory, Guangxi Medical University Cancer Hospital, Nanning, China.
Frontiers in immunology
|March 12, 2025
概括
扩散标志物Ki67 (MKI67) 在不同类型的癌症中具有不同的预后价值. 这项泛癌研究揭示了Ki67与某些癌症的不良结果,但在其他癌症的良好结果有关,这影响了临床适用性.
科学领域:
- 在瘤学瘤学.
- 癌症生物标志物 癌症生物标志物
- 免疫学 免疫学 免疫学
背景情况:
- 扩散标志物Ki67 (MKI67) 被广泛使用,但其预后值因癌症类型而异.
- 缺乏对Ki67在不同癌症的具体预后影响的清晰理解.
- 这项研究解决了对Ki67的预后价值进行全面泛癌分析的需求.
研究的目的:
- 为了对Ki67 (MKI67) 的预后价值进行瘤分析.
- 探索MKI67表达和生存,临床特征和瘤微环境之间的相关性.
- 通过公共数据库和大量中国癌症患者队列验证发现.
主要方法:
- 利用癌症基因组图谱 (TCGA) 数据库进行全癌症分析.
- 对来自中国的10028名患者进行了免疫组织化学和相关性分析.
- 采用xCell和TIMER算法来评估瘤透免疫细胞和MKI67表达.
主要成果:
- 在多种癌症类型中,MKI67表达显著上调.
- Ki67与肺腺癌 (LUAD),肺状细胞癌 (LUSC),肝肝细胞癌 (LIHC) 和乳腺癌 (BRCA) 的预后不佳有关.
- 相反,Ki67在结肠腺癌 (COAD),结肠直肠腺癌 (READ) 和直肠腺癌 (READ) 中显示出良好的预后,并且与免疫细胞透率的增加相关.
结论:
- 基67的预后值是癌症类型的特异性,需要仔细的临床解释.
- 研究结果为Ki67作为生物标志物在各种癌症环境中的应用提供了指导.
- 这项研究支持Ki67在改善临床决策和患者结果方面的潜力.
相关概念视频
01:24Kaplan-Meier Approach
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...